To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Gemfibrozil

Criteria

Inclusion Criteria:

• Patients with confirmed Type 2 diabetes mellitus for at least 1 year and treated with metformin.

• Body mass index between ≥19 and ≤42 kg/m2.

Exclusion Criteria:

• Intake of another investigational drug within the last 30 days prior to enrolment.

• Clinically significant illness or clinically relevant trauma.